Go Pro
→ Stranded On The Flood Plains of History (From Porter & Company) (Ad)tc pixel Free OTLK Stock Alerts

Oncobiologics (OTLK) Financials

Oncobiologics logo
$1.42 -0.03 (-2.07%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$1.41 -0.01 (-0.92%)
As of 07/6/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Oncobiologics

Annual Income Statements for Oncobiologics

This table shows Oncobiologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Net Income / (Loss) Attributable to Common Shareholders		 -53 -63 -40 -48 -36 -49 -53 -66 -59 -75
Consolidated Net Income / (Loss)		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Net Income / (Loss) Continuing Operations		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Total Pre-Tax Income 		-49 -53 -38 -34 -38 -39 -53 -66 -59 -75
Total Operating Income		 -47 -51 -36 -30 -36 -37 -52 -63 -53 -72
Total Gross Profit		 5.22 2.98 3.81 3.09 8.15 0.00 0.00 0.00 0.00 0.00
Total Revenue		 5.22 2.98 3.81 3.09 8.15 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 52 54 40 33 44 37 52 63 53 72
Selling, General & Admin Expense		 13 22 16 14 9.37 9.97 13 21 27 30
Research & Development Expense		 39 33 24 19 24 26 39 42 26 42
Total Other Income / (Expense), net		 -2.30 -1.85 -2.47 -4.10 -1.64 -1.67 -1.43 -2.98 -5.85 -3.66
Interest Expense		 2.30 1.85 5.63 5.14 4.07 3.65 0.94 2.51 3.11 41
Interest & Investment Income		 - - - - - 0.00 -0.05 -0.05 0.96 0.81
Other Income / (Expense), net		 - - 3.16 1.05 2.44 1.98 -0.45 -0.42 -3.71 36
Income Tax Expense		 -0.19 0.10 0.50 -3.65 -3.41 -3.27 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($5.43) ($3.67) ($1.67) ($9.74) ($1.98) ($0.67) ($0.35) ($0.31) ($4.72) ($4.06)
Weighted Average Basic Shares Outstanding		 9.75M 17.21M 24.02M 4.93M 18.19M 72.56M 152.68M 212.08M 12.51M 18.55M
Diluted Earnings per Share		 ($5.43) ($3.67) ($1.80) ($9.74) ($1.98) ($0.67) ($0.35) ($0.31) ($4.72) ($4.06)
Weighted Average Diluted Shares Outstanding		 9.75M 17.21M 24.04M 4.93M 18.19M 72.56M 152.68M 212.08M 12.51M 18.55M
Weighted Average Basic & Diluted Shares Outstanding		 9.75M 17.21M 25.53M 4.93M 18.19M 72.56M 224.26M 228.21M 260.26M 24.91M

Quarterly Income Statements for Oncobiologics

This table shows Oncobiologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45
Consolidated Net Income / (Loss)		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45
Net Income / (Loss) Continuing Operations		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45
Total Pre-Tax Income 		-13 0.00 -114 44 5.69 17 -46 -20 -23 -4.45
Total Operating Income		 -12 -10 -19 -20 -23 -22 -12 -16 -13 -14
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 1.07 -1.24 -0.02
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 1.51 -1.21 0.13
Operating Revenue		 - - - 0.00 - 0.00 0.00 1.51 -1.21 0.13
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.44 0.03 0.15
Operating Cost of Revenue		 - - - 0.00 - 0.00 0.00 0.44 0.03 0.15
Total Operating Expenses		 12 10 19 20 23 22 12 17 12 14
Selling, General & Admin Expense		 7.51 5.79 5.43 8.36 10 12 7.98 9.68 8.61 9.50
Research & Development Expense		 4.94 4.53 14 11 13 9.66 4.41 7.13 3.63 4.50
Total Other Income / (Expense), net		 -0.53 -0.86 -95 64 29 39 -34 -4.40 -9.57 9.57
Interest Expense		 0.27 -0.19 37 -0.40 0.26 -0.05 0.02 0.05 0.00 -0.29
Interest & Investment Income		 0.57 0.00 -0.03 -0.06 0.49 - -0.04 -0.03 -0.04 -0.05
Other Income / (Expense), net		 -0.83 -1.05 -58 64 28 39 -34 -4.32 -9.54 9.33
Income Tax Expense		 - - 0.00 0.00 - - 0.00 0.00 - 0.00
Basic Earnings per Share		 ($1.04) ($0.86) ($8.01) $1.91 $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05)
Weighted Average Basic Shares Outstanding		 12.51M 13.01M 14.27M 23.23M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M
Diluted Earnings per Share		 ($1.04) ($0.86) ($8.01) ($0.89) $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05)
Weighted Average Diluted Shares Outstanding		 12.51M 13.01M 14.27M 25.48M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M
Weighted Average Basic & Diluted Shares Outstanding		 260.26M 260.26M 23.41M 23.66M 24.91M 32.02M 33.57M 44.42M 83.07M 120.86M

Annual Cash Flow Statements for Oncobiologics

This table details how cash moves in and out of Oncobiologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Net Change in Cash & Equivalents		 6.72 -6.72 0.83 -1.47 6.30 4.52 1.94 2.92 6.00 -8.46
Net Cash From Operating Activities		 -27 -45 -16 -33 -32 -32 -54 -57 -43 -69
Net Cash From Continuing Operating Activities		 -27 -45 -16 -33 -32 -32 -54 -57 -43 -69
Net Income / (Loss) Continuing Operations		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Consolidated Net Income / (Loss)		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Depreciation Expense		 1.82 2.39 2.69 3.05 3.36 0.55 0.26 0.20 0.04 0.11
Non-Cash Adjustments To Reconcile Net Income		 11 12 9.49 7.68 12 4.00 5.58 11 11 9.48
Changes in Operating Assets and Liabilities, net		 8.18 -7.05 11 -14 -13 -1.11 -6.93 -1.64 4.78 -3.02
Net Cash From Investing Activities		 -8.80 -1.10 -0.29 -2.78 -0.44 -0.90 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 -8.80 -1.10 -0.29 -2.78 -0.44 -0.90 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 43 40 17 34 39 37 56 60 49 60
Net Cash From Continuing Financing Activities		 43 40 17 34 39 37 56 60 49 60
Repayment of Debt		 -9.30 -14 -3.71 -2.08 -6.42 -0.05 -3.67 -13 -11 0.00
Issuance of Debt		 11 1.03 15 - 0.00 0.90 10 10 30 0.00
Issuance of Common Equity		 42 53 1.61 15 46 35 46 62 30 60
Other Financing Activities, net		 -0.00 3.81 0.25 - -0.52 0.92 3.56 0.18 -0.01 -0.00
Cash Interest Paid		 1.40 2.06 1.34 0.11 2.79 0.91 0.05 1.56 1.16 0.48

Quarterly Cash Flow Statements for Oncobiologics

This table details how cash moves in and out of Oncobiologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -10 -13 37 -15 -17 -9.22 1.85 1.34 0.59 -0.93
Net Cash From Operating Activities		 -13 -13 -19 -20 -17 -11 -17 -12 -15 -7.83
Net Cash From Continuing Operating Activities		 -13 -13 -19 -20 -17 -11 -17 -12 -15 -7.83
Net Income / (Loss) Continuing Operations		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45
Consolidated Net Income / (Loss)		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45
Depreciation Expense		 0.01 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Non-Cash Adjustments To Reconcile Net Income		 2.23 2.32 96 -62 -27 -35 36 6.04 10 -8.82
Changes in Operating Assets and Liabilities, net		 -1.99 -4.20 -1.26 -1.78 4.22 6.90 -5.91 2.19 -2.37 5.41
Net Cash From Financing Activities		 2.42 -0.00 56 4.31 -0.11 1.74 18 13 16 6.90
Net Cash From Continuing Financing Activities		 2.42 -0.00 56 4.31 -0.11 1.74 18 13 16 6.90
Issuance of Common Equity		 2.43 0.00 56 4.31 -0.11 1.74 1.42 14 15 6.90

Annual Balance Sheets for Oncobiologics

This table presents Oncobiologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 35 25 21 22 17 20 23 29 32 29 19
Total Current Assets		 15 5.68 3.90 3.30 14 18 22 28 31 27 17
Cash & Equivalents		 9.07 2.35 3.19 1.72 8.02 13 14 17 23 15 8.08
Accounts Receivable		 0.02 - - - - - - - - 0.00 1.49
Inventories, net		 - - - - - - - - - 0.00 3.34
Prepaid Expenses		 1.79 3.33 0.72 1.59 4.99 5.41 7.03 10 7.59 12 4.48
Plant, Property, & Equipment, net		 18 19 16 18 3.18 0.33 0.16 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 2.08 1.07 0.74 0.49 0.46 1.46 1.14 1.01 1.32 1.41 1.20
Long-Term Investments		 - - - - - 0.00 0.85 0.80 0.79 0.69 0.55
Other Noncurrent Operating Assets		 1.87 0.85 0.74 0.49 0.46 1.46 0.29 0.20 0.53 0.71 0.64
Total Liabilities & Shareholders' Equity		 35 25 21 22 17 20 23 29 32 29 19
Total Liabilities		 63 31 51 43 28 17 18 20 47 102 51
Total Current Liabilities		 37 20 29 32 20 16 6.75 20 47 43 46
Short-Term Debt		 16 6.18 5.01 14 11 3.66 0.90 11 36 29 30
Accounts Payable		 12 5.07 11 3.61 2.28 2.39 2.20 3.49 6.57 7.97 10
Accrued Expenses		 5.92 6.12 7.34 6.46 4.62 7.76 1.73 3.43 2.75 3.24 5.31
Current Deferred & Payable Income Tax Liabilities		 1.75 1.85 2.35 1.86 1.86 1.86 1.86 1.86 1.86 1.86 0.30
Other Current Liabilities		 - - - 4.61 0.19 0.22 0.07 0.04 0.00 0.05 0.06
Total Noncurrent Liabilities		 26 10 23 11 7.61 1.02 11 0.06 0.01 59 4.96
Long-Term Debt		 4.92 2.23 13 0.10 0.05 0.90 11 - - 0.00 0.00
Other Noncurrent Operating Liabilities		 0.28 2.43 4.84 4.74 7.56 0.11 0.57 0.06 0.01 59 4.96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -55 -5.17 -34 -26 -16 2.83 4.61 8.74 -14 -73 -32
Total Preferred & Common Equity		 -54 -5.17 -34 -26 -16 2.83 4.61 8.74 -14 -73 -32
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -54 -5.17 -34 -26 -16 2.83 4.61 8.74 -14 -73 -32
Common Stock		 40 142 153 191 238 293 347 418 453 470 574
Retained Earnings		 -94 -147 -186 -216 -254 -290 -343 -409 -468 -543 -606

Quarterly Balance Sheets for Oncobiologics

This table presents Oncobiologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026
Total Assets		 22 59 47 17 19 22 18 22
Total Current Assets		 20 58 46 16 18 21 17 21
Cash & Equivalents		 10 47 32 5.70 7.56 8.90 8.68 7.75
Accounts Receivable		 - - - - - 1.75 0.11 2.72
Inventories, net		 - - - 3.11 3.60 4.13 3.46 3.34
Prepaid Expenses		 10 11 14 6.86 6.65 6.32 4.92 7.09
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.30 1.24 1.47 1.34 1.27 1.30 1.07 0.99
Long-Term Investments		 0.80 0.77 0.71 0.66 0.62 0.59 0.51 0.47
Other Noncurrent Operating Assets		 0.50 0.48 0.77 0.68 0.64 0.70 0.56 0.52
Total Liabilities & Shareholders' Equity		 22 59 47 17 19 22 18 22
Total Liabilities		 46 193 131 67 52 60 57 51
Total Current Liabilities		 46 54 43 48 25 31 49 39
Short-Term Debt		 37 45 32 31 12 14 37 16
Accounts Payable		 3.48 4.36 5.55 12 7.77 10 7.32 14
Accrued Expenses		 4.09 3.12 2.68 3.39 3.15 5.31 4.71 9.04
Current Deferred & Payable Income Tax Liabilities		 1.86 1.86 1.86 1.86 1.86 1.86 0.30 0.30
Other Current Liabilities		 0.00 0.00 0.03 0.05 0.05 0.06 0.06 0.06
Total Noncurrent Liabilities		 0.06 139 88 19 27 28 7.73 12
Long-Term Debt		 - - - - 21 20 - 11
Other Noncurrent Operating Liabilities		 0.06 139 88 19 5.67 7.66 7.73 0.88
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -24 -134 -84 -50 -32 -37 -39 -29
Total Preferred & Common Equity		 -24 -134 -84 -50 -32 -37 -39 -29
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -24 -134 -84 -50 -32 -37 -39 -29
Common Stock		 455 459 465 476 540 555 590 604
Retained Earnings		 -479 -593 -549 -526 -572 -592 -629 -633

Annual Metrics And Ratios for Oncobiologics

This table displays calculated financial ratios and metrics derived from Oncobiologics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -42.91% 27.92% -18.99% 163.84% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -9.42% 38.66% 14.94% -19.41% -12.48% -51.34% -21.89% 10.26% 37.65%
EBIT Growth		 0.00% -10.28% 36.27% 12.61% -18.41% -2.95% -49.69% -21.67% 10.48% 37.50%
NOPAT Growth		 0.00% -10.28% 30.12% 17.38% -22.45% -1.49% -40.41% -21.93% 15.77% -34.97%
Net Income Growth		 0.00% -9.52% 27.12% 22.54% -14.73% -2.07% -50.86% -24.24% 10.70% -27.78%
EPS Growth		 0.00% 32.41% 50.95% 22.54% 79.67% 66.16% 47.76% 11.43% 10.70% 13.98%
Operating Cash Flow Growth		 0.00% -65.53% 65.91% -113.09% 2.27% 1.55% -70.66% -4.46% 24.18% -60.08%
Free Cash Flow Firm Growth		 0.00% 0.00% 83.34% -259.58% 25.18% -20.77% -51.26% -4.99% 26.65% 118.34%
Invested Capital Growth		 0.00% 106.65% -1,665.36% 66.38% -42.00% 30.48% 120.74% 35.94% -311.93% -1,828.51%
Revenue Q/Q Growth		 0.00% 0.00% 171.42% -40.83% 165.82% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 25.48% -43.23% -2.91% 5.01% -7.56% -0.72% 1.13% 34.65%
EBIT Q/Q Growth		 0.00% 0.00% 23.76% -37.93% -2.82% 6.98% -7.46% -0.72% 1.20% 34.55%
NOPAT Q/Q Growth		 0.00% 0.00% 16.41% -47.18% -0.77% 6.78% -7.08% -0.88% 2.80% -17.00%
Net Income Q/Q Growth		 0.00% 0.00% 9.75% -24.01% 5.74% 0.49% -7.01% -1.44% 2.24% 19.86%
EPS Q/Q Growth		 0.00% 0.00% -2.27% -24.01% -18.56% -24.07% -20.69% -3.33% 2.24% -0.25%
Operating Cash Flow Q/Q Growth		 0.00% 1.39% 40.26% -34.50% 7.06% -23.92% 5.38% -2.27% -6.15% -6.57%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -15.01% 3.30% -42.61% 8.51% -2.78% -11.60% -83.26%
Invested Capital Q/Q Growth		 0.00% 0.00% -28.10% -758.87% -1,705.97% 38.84% -74.25% -60.90% 41.82% 29.43%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -857.18% -1,642.95% -787.87% -827.26% -374.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -892.13% -1,723.30% -941.36% -960.12% -445.60% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -892.13% -1,723.30% -858.50% -926.19% -415.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -932.51% -1,788.91% -1,019.26% -974.62% -423.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.61% 100.19% 101.31% 89.19% 91.01% 91.50% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.93% 103.61% 117.19% 117.99% 112.03% 110.48% 101.88% 104.03% 103.78% 212.16%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 176.64% 325.75% 216.43% 116.78% 218.64% 887.24% -1,430.33% -989.99% 2,069.13% 172.24%
Cash Return on Invested Capital (CROIC)		 0.00% -5,233.87% 0.00% 0.00% 0.00% 0.00% -3,977.23% -3,539.46% 0.00% 0.00%
Operating Return on Assets (OROA)		 -133.00% -169.98% -141.84% -132.95% -171.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -139.02% -176.45% -168.40% -139.91% -175.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 347.61% 591.20% 234.06% 134.13% 288.52% 1,485.83% -1,430.33% -989.99% 2,069.13% 172.24%
Return on Equity Simple (ROE_SIMPLE)		 89.76% 1,030.41% 115.45% 117.80% 214.04% -1,246.85% -1,153.86% -756.04% 408.53% 103.13%
Net Operating Profit after Tax (NOPAT)		 -33 -36 -25 -21 -25 -26 -36 -44 -37 -50
NOPAT Margin		 -624.49% -1,206.31% -658.95% -672.08% -311.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 126.81% 184.28% 128.38% 60.59% 96.08% -411.22% -294.61% -404.57% 1,068.77% 199.92%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -176.14% 115.02%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 247.27% 723.71% 416.69% 460.81% 115.02% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 744.86% 1,099.59% 624.68% 599.31% 292.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 992.13% 1,823.30% 1,041.36% 1,060.12% 545.60% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -47 -51 -33 -29 -34 -35 -52 -63 -57 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -49 -30 -26 -30 -34 -52 -63 -57 -35
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 32.40 82.58 31.58 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 32.40 82.58 31.58 0.00 0.00
Price to Revenue (P/Rev)		 0.00 32.53 8.87 22.92 5.16 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 104.35 0.00 0.00 0.00 0.00 353.44 185.27 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 34.67 13.63 29.50 6.24 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.39
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -0.80 -1.69 -0.60 -0.83 -1.06 1.62 2.56 1.25 -2.46 -0.40
Long-Term Debt to Equity		 -0.22 -0.49 -0.44 -0.17 0.00 0.32 2.36 0.00 0.00 0.00
Financial Leverage		 -0.46 -0.58 -0.60 -0.60 -0.60 0.58 -1.55 -0.81 -0.72 -0.29
Leverage Ratio		 -1.27 -1.85 -1.29 -0.83 -1.25 -4.64 5.72 3.85 -10.67 -0.70
Compound Leverage Factor		 -1.33 -1.91 -1.51 -0.98 -1.40 -5.13 5.83 4.00 -11.07 -1.48
Debt to Total Capital		 -392.83% 245.39% -149.62% -495.94% 1,842.72% 61.77% 71.90% 55.54% 168.38% -67.47%
Short-Term Debt to Total Capital		 -282.97% 173.59% -40.67% -394.23% 1,834.59% 49.54% 5.51% 55.54% 168.38% -67.47%
Long-Term Debt to Total Capital		 -109.86% 71.80% -108.95% -101.71% 8.14% 12.23% 66.39% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -476.99% 0.00% -23.76% -135.58% 867.22% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 969.82% -145.39% 273.38% 731.52% -2,609.95% 38.23% 28.10% 44.46% -68.38% 167.47%
Debt to EBITDA		 -0.49 -0.18 -0.61 -0.68 -0.37 -0.13 -0.23 -0.17 -0.63 -0.83
Net Debt to EBITDA		 -0.29 -0.13 -0.51 -0.61 -0.11 0.23 0.07 0.12 -0.20 -0.39
Long-Term Debt to EBITDA		 -0.14 -0.05 -0.45 -0.14 0.00 -0.03 -0.21 0.00 0.00 0.00
Debt to NOPAT		 -0.67 -0.24 -0.73 -0.83 -0.45 -0.18 -0.33 -0.25 -0.96 -0.59
Net Debt to NOPAT		 -0.40 -0.18 -0.61 -0.75 -0.13 0.31 0.10 0.17 -0.31 -0.28
Long-Term Debt to NOPAT		 -0.19 -0.07 -0.53 -0.17 0.00 -0.04 -0.30 0.00 0.00 0.00
Altman Z-Score		 0.00 -13.47 -18.64 -18.25 -26.41 -23.01 -15.28 -18.72 -25.93 -30.34
Noncontrolling Interest Sharing Ratio		 -96.79% -81.49% -8.15% -14.86% -31.96% -67.47% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.41 0.28 0.14 0.10 0.67 1.13 3.19 1.39 0.66 0.64
Quick Ratio		 0.25 0.12 0.11 0.05 0.40 0.79 2.14 0.88 0.50 0.35
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -52 -8.63 -31 -23 -28 -42 -45 -33 5.99
Operating Cash Flow to CapEx		 -312.08% -4,141.64% -5,308.39% -1,187.99% -7,383.83% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -27.98 -1.53 -6.03 -5.70 -7.68 -45.31 -17.72 -10.51 0.15
Operating Cash Flow to Interest Expense		 -11.96 -24.56 -2.76 -6.42 -7.93 -8.70 -57.96 -22.55 -13.82 -1.69
Operating Cash Flow Less CapEx to Interest Expense		 -15.79 -25.15 -2.81 -6.96 -8.03 -8.70 -57.96 -22.55 -13.82 -1.69
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.15 0.10 0.17 0.14 0.41 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 260.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.29 0.16 0.22 0.18 0.75 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 1.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 1.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -15 0.99 -15 -5.21 -7.40 -5.14 1.07 1.45 -3.07 -59
Invested Capital Turnover		 -0.35 -0.43 -0.53 -0.30 -1.29 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 16 -16 10 -2.19 2.25 6.21 0.38 -4.52 -56
Enterprise Value (EV)		 0.00 103 52 91 51 84 377 269 69 140
Market Capitalization		 0.00 97 34 71 42 92 380 276 58 126
Book Value per Share		 ($5.56) ($0.23) ($1.36) ($0.35) ($0.57) $0.02 $0.03 $0.04 ($0.06) ($3.09)
Tangible Book Value per Share		 ($5.56) ($0.23) ($1.36) ($0.35) ($0.57) $0.02 $0.03 $0.04 ($0.06) ($3.09)
Total Capital		 -5.59 3.56 -12 -3.49 0.62 7.39 16 20 21 -44
Total Debt		 22 8.73 18 17 11 4.57 12 11 36 29
Total Long-Term Debt		 6.14 2.55 13 3.55 0.05 0.90 11 0.00 0.00 0.00
Net Debt		 13 6.38 15 16 3.37 -7.97 -3.54 -7.29 11 14
Capital Expenditures (CapEx)		 8.80 1.10 0.29 2.78 0.44 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -11 -23 -17 -3.47 -6.82 1.18 1.31 -3.59 -0.63
Debt-free Net Working Capital (DFNWC)		 -6.06 -8.58 -20 -15 4.55 5.72 16 19 20 14
Net Working Capital (NWC)		 -22 -15 -25 -29 -6.79 2.06 15 7.79 -16 -15
Net Nonoperating Expense (NNE)		 16 17 14 9.34 9.11 9.45 17 22 22 25
Net Nonoperating Obligations (NNO)		 13 6.16 15 16 3.37 -7.97 -3.54 -7.29 11 14
Total Depreciation and Amortization (D&A)		 1.82 2.39 2.69 3.05 3.36 0.55 0.26 0.20 0.04 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 -289.86% -366.97% -603.76% -540.56% -42.55% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 -116.06% -288.03% -520.18% -484.94% 55.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 -419.17% -495.32% -651.53% -930.82% -83.34% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($868.80) ($587.20) ($267.20) ($195.20) ($39.60) ($13.40) ($7.00) ($6.20) ($4.80) ($4.06)
Adjusted Weighted Average Basic Shares Outstanding		 60.96K 147.37K 150.14K 246.61K 1.51M 6.36M 7.63M 10.60M 12.51M 18.55M
Adjusted Diluted Earnings per Share		 ($868.80) ($587.20) ($288.00) ($195.20) ($39.60) ($13.40) ($7.00) ($6.20) ($4.80) ($4.06)
Adjusted Weighted Average Diluted Shares Outstanding		 60.96K 147.37K 150.26K 246.61K 1.51M 6.36M 7.63M 10.60M 12.51M 18.55M
Adjusted Basic & Diluted Earnings per Share		 ($868.80) ($587.20) $0.00 $0.00 ($39.60) ($13.40) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.96K 107.58K 159.57K 531.82K 909.59K 3.63M 11.21M 11.41M 13.01M 24.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -36 -25 -21 -18 -25 -36 -44 -37 -50
Normalized NOPAT Margin		 -624.49% -1,206.31% -658.95% -672.08% -215.07% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -936.15% -1,785.46% -1,006.10% -1,092.78% -465.68% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -20.27 -27.73 -5.82 -5.56 -8.31 -9.54 -55.74 -25.27 -18.28 -0.87
NOPAT to Interest Expense		 -14.19 -19.41 -4.46 -4.03 -6.24 -7.06 -38.68 -17.57 -11.96 -1.23
EBIT Less CapEx to Interest Expense		 -24.10 -28.32 -5.87 -6.10 -8.42 -9.54 -55.74 -25.27 -18.28 -0.87
NOPAT Less CapEx to Interest Expense		 -18.02 -20.00 -4.52 -4.58 -6.34 -7.06 -38.68 -17.57 -11.96 -1.23
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -8.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Oncobiologics

This table displays calculated financial ratios and metrics derived from Oncobiologics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 260,245,017.00 260,245,017.00 260,257,517.00 23,405,637.00 - - 32,017,179.00 33,568,023.00 44,419,529.00 83,067,190.00
DEI Adjusted Shares Outstanding		 13,012,251.00 13,012,251.00 13,012,876.00 23,405,637.00 - - 32,017,179.00 33,568,023.00 44,419,529.00 83,067,190.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.00 -0.86 -8.78 1.90 - - -1.45 -0.60 -0.52 -0.05
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 4.65% 27.52% -1,031.14% 309.44% 141.39% 253.34% 39.94% -145.46% -232.19% 89.92%
EBIT Growth		 4.92% 27.39% -1,029.73% 309.19% 141.14% 252.71% 39.93% -145.55% -232.59% 89.86%
NOPAT Growth		 10.93% 34.20% -176.98% -54.05% -162.32% -109.31% 34.57% 43.65% 56.32% -13.20%
Net Income Growth		 9.44% 40.10% -1,617.52% 314.80% 143.81% 255.46% 59.44% -145.38% -232.69% 90.39%
EPS Growth		 9.44% 40.10% -1,440.38% 44.72% 129.81% 183.72% 81.27% 38.20% -152.78% 96.67%
Operating Cash Flow Growth		 -24.30% -46.41% -137.44% -47.64% -33.28% 15.84% 13.93% 39.01% -36.21% 52.80%
Free Cash Flow Firm Growth		 58.73% -165.06% 3,960.45% 1,693.85% 893.26% 185.35% -213.48% -239.95% -553.63% 94.82%
Invested Capital Growth		 -311.93% 118.74% -6,361.29% -1,490.06% -1,828.51% -2,573.44% 94.47% 85.42% 57.23% -34.81%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 110.55%
EBITDA Q/Q Growth		 36.93% 14.58% -579.34% 157.23% -88.43% 216.47% -366.06% 56.68% 0.00% 79.72%
EBIT Q/Q Growth		 36.91% 14.44% -577.90% 157.17% -88.48% 217.61% -366.67% 56.65% 0.00% 79.61%
NOPAT Q/Q Growth		 31.32% 17.14% -83.47% -47.55% -16.94% 33.89% 59.86% -27.09% 0.00% -4.03%
Net Income Q/Q Growth		 37.17% 13.95% -922.42% 138.86% -87.18% 205.34% -366.76% 56.53% 0.00% 80.69%
EPS Q/Q Growth		 37.17% 13.95% -831.40% 88.89% 134.83% 132.26% -308.33% 63.33% 0.00% 86.84%
Operating Cash Flow Q/Q Growth		 3.59% -2.28% -47.85% -1.27% 12.97% 35.42% -51.21% 28.24% 0.00% 47.60%
Free Cash Flow Firm Q/Q Growth		 -13.18% -230.15% 980.81% -51.57% -43.67% -64.48% -2,690.18% 40.28% 0.00% 70.44%
Invested Capital Q/Q Growth		 41.82% 134.09% -13,225.35% 38.92% 29.43% 56.28% 70.68% -61.19% 0.00% 7.56%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 70.78% 0.00% -17.18%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,331.47% 0.00% -3,659.12%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,046.20% 0.00% -11,006.82%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,333.42% 0.00% -3,682.99%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,338.75% 0.00% -3,494.28%
Tax Burden Percent		 100.00% 0.00% 100.00% 100.00% 100.00% 0.00% 100.01% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.76% 0.00% 148.28% 100.79% 104.11% 0.00% 100.12% 100.40% 100.17% 94.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2,069.13% 1,199.76% 257.19% 210.93% 172.24% 125.44% -25.34% 71.88% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% -3,825.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.78% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -58.01% 0.00% 0.00%
Return on Common Equity (ROCE)		 2,069.13% 1,199.76% 257.19% 210.93% 172.24% 125.44% -25.34% 71.88% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 211.55% 118.55% 0.00% 0.00% 93.08% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.72 -7.23 -13 -20 -23 -15 -8.67 -11 -9.44 -9.82
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -732.34% 0.00% -7,704.78%
Net Nonoperating Expense Percent (NNEP)		 209.37% 195.47% -1,273.59% 161,683.96% -226.88% -130.60% 348.67% 74.09% 52.53% -24.60%
Return On Investment Capital (ROIC_SIMPLE)		 -41.31% -59.23% 14.81% 38.18% 52.43% 77.38% -1,489.38% 400.48% 499.55% 484.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.22% 0.00% 117.18%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 643.02% 0.00% 7,458.14%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 473.97% 0.00% 3,531.51%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,116.98% 0.00% 10,989.65%
Earnings before Interest and Taxes (EBIT)		 -13 -11 -77 44 5.47 17 -46 -20 -23 -4.69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -11 -77 44 5.50 17 -46 -20 -23 -4.66
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 35.68 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 1.85 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.07% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 122.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 52.25 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 2.65 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 2.67 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 1.63 4.82 23.39 0.00 0.00 0.00 0.00 13.55
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -2.46 -1.50 -0.33 -0.39 -0.40 -0.61 -1.02 -0.93 -0.95 -0.93
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 -0.65 -0.55 0.00 -0.38
Financial Leverage		 -0.72 -0.47 0.13 0.00 -0.29 -0.67 -0.13 -0.20 -0.58 -0.71
Leverage Ratio		 -10.67 -9.83 -0.91 -1.03 -0.70 -0.52 -0.47 -0.57 -0.40 -0.67
Compound Leverage Factor		 -10.43 0.00 -1.35 -1.03 -0.73 0.00 -0.47 -0.58 -0.40 -0.63
Debt to Total Capital		 168.38% 299.53% -50.00% -63.29% -67.47% -157.29% 5,673.98% -1,251.01% -1,940.23% -1,331.30%
Short-Term Debt to Total Capital		 168.38% 299.53% -50.00% -63.29% -67.47% -157.29% 2,060.46% -508.59% -1,940.23% -782.17%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,613.53% -742.43% 0.00% -549.12%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -68.38% -199.53% 150.00% 163.29% 167.47% 257.29% -5,573.98% 1,351.01% 2,040.23% 1,431.30%
Debt to EBITDA		 -0.63 -0.70 -0.36 -0.56 -0.83 -4.60 1.37 -0.86 0.00 0.00
Net Debt to EBITDA		 -0.20 -0.48 0.03 0.01 -0.39 -3.65 1.03 -0.62 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.87 -0.51 0.00 0.00
Debt to NOPAT		 -0.96 -1.09 -1.07 -0.76 -0.59 -0.53 -0.43 -0.68 0.00 0.00
Net Debt to NOPAT		 -0.31 -0.76 0.08 0.01 -0.28 -0.42 -0.33 -0.49 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.28 -0.40 0.00 0.00
Altman Z-Score		 -21.49 -32.74 -17.82 -12.36 -25.65 -41.80 -50.00 -39.95 -53.79 -41.99
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.66 0.44 1.07 1.07 0.64 0.32 0.72 0.67 0.35 0.54
Quick Ratio		 0.50 0.23 0.87 0.75 0.35 0.12 0.30 0.34 0.18 0.27
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.20 -14 122 59 33 12 -139 -83 -24 -7.17
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -15.54 0.00 3.28 0.00 127.32 0.00 -7,489.07 -1,676.81 0.00 0.00
Operating Cash Flow to Interest Expense		 -47.17 0.00 -0.52 0.00 -64.91 0.00 -896.32 -241.15 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -47.17 0.00 -0.52 0.00 -64.91 0.00 -896.32 -241.15 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6,562.23 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6,562.23 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.07 1.05 -137 -84 -59 -26 -7.60 -12 -11 -10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.52 6.64 -135 -79 -56 -27 130 72 15 -2.65
Enterprise Value (EV)		 69 128 152 172 140 71 64 79 98 36
Market Capitalization		 58 103 155 173 126 47 39 54 70 17
Book Value per Share		 ($0.06) ($1.87) ($0.52) ($3.57) ($3.09) ($2.02) ($1.01) ($1.11) ($0.64) ($0.35)
Tangible Book Value per Share		 ($0.06) ($1.87) ($0.52) ($3.57) ($3.09) ($2.02) ($1.01) ($1.11) ($0.64) ($0.35)
Total Capital		 21 12 -89 -51 -44 -20 0.58 -2.75 -1.89 -2.03
Total Debt		 36 37 45 32 29 31 33 34 37 27
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 21 20 0.00 11
Net Debt		 11 25 -3.25 -0.30 14 24 25 25 27 19
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.59 0.61 1.22 3.47 -0.63 -7.53 -2.57 -5.29 -3.91 -9.88
Debt-free Net Working Capital (DFNWC)		 20 11 48 35 14 -1.83 4.98 3.61 4.77 -2.13
Net Working Capital (NWC)		 -16 -26 3.71 3.06 -15 -33 -7.02 -10 -32 -18
Net Nonoperating Expense (NNE)		 4.27 3.95 101 -64 -29 -33 38 9.13 14 -5.37
Net Nonoperating Obligations (NNO)		 11 25 -3.25 -0.30 14 24 25 25 27 19
Total Depreciation and Amortization (D&A)		 0.01 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -351.65% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 239.64% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -690.40% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($20.80) ($0.80) ($8.01) $1.91 $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 625.44K 13.01M 14.27M 23.23M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M
Adjusted Diluted Earnings per Share		 ($20.80) ($0.80) ($8.01) ($0.89) $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 625.44K 13.01M 14.27M 25.48M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M
Adjusted Basic & Diluted Earnings per Share		 ($20.80) $0.00 $0.00 $0.00 $0.31 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.01M 13.01M 23.41M 23.66M 24.91M 32.02M 33.57M 44.42M 83.07M 120.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.72 -7.23 -13 -14 -16 -15 -8.67 -11 -9.44 -9.82
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -732.34% 0.00% -7,704.78%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,338.75% 0.00% -3,494.28%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -49.19 0.00 -2.07 0.00 20.90 0.00 -2,502.40 -406.72 0.00 0.00
NOPAT to Interest Expense		 -32.29 0.00 -0.36 0.00 -87.45 0.00 -468.82 -223.38 0.00 0.00
EBIT Less CapEx to Interest Expense		 -49.19 0.00 -2.07 0.00 20.90 0.00 -2,502.40 -406.72 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -32.29 0.00 -0.36 0.00 -87.45 0.00 -468.82 -223.38 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Outlook Therapeutics (NASDAQ: OTLK) shows a company that is still highly dependent on financing and remains financially strained, despite some recent improvement in operating cash burn and balance sheet liquidity.

Over the last four years, the biggest trend is that OTLK has repeatedly posted large losses and negative operating cash flow, with only occasional quarters of positive net income driven by non-operating items. Revenue has been inconsistent and, in several quarters, effectively nonexistent. Meanwhile, the company has relied heavily on equity issuance and debt to fund operations.

  • Cash and equivalents improved from $5.7 million at Q1 2025 to $7.7 million at Q2 2026, indicating the company has preserved some liquidity.
  • Operating cash outflow improved sharply year over year in Q2 2026, with operating cash burn of $(7.8) million versus $(16.6) million in Q2 2025.
  • Q2 2026 operating expenses fell to $14.0 million from $21.6 million in Q1 2026, showing better cost control sequentially.
  • Short-term debt declined to $15.8 million in Q2 2026 from $36.7 million in Q1 2026, a meaningful reduction in near-term debt pressure.
  • Long-term debt also improved to $11.1 million in Q2 2026 from $20.4 million in Q3 2025.
  • Share count trends suggest the company raised capital when needed, which helped support the balance sheet and cash position.
  • OTLK reported $127 thousand of revenue in Q2 2026, but this is too small to indicate a durable commercial trend.
  • Q2 2026 gross profit was still slightly negative at $(22 thousand), so the company is not yet operating profitably at the product level.
  • The company posted a Q2 2026 net loss of $(4.5) million, extending a long history of losses.
  • Balance sheet leverage remains heavy, with total liabilities of $50.9 million versus total assets of only $21.9 million in Q2 2026.
  • Stockholders’ equity remained deeply negative at $(29.0) million, highlighting continued financial weakness.
  • Revenue has been highly volatile and often zero, making it difficult to see a stable commercial foundation.
  • The company has repeatedly depended on equity financing, including $6.9 million in Q2 2026 and $15.5 million in Q1 2026, which can dilute shareholders.
  • Large “other income/expense” swings have materially affected reported earnings, suggesting bottom-line results are not driven by core operations.

Bottom line: OTLK’s recent quarters show some progress on liquidity and cash burn, but the company remains a highly speculative, financing-dependent biotech with negative equity, recurring losses, and little evidence of consistent revenue generation. Investors should view the recent improvements as early signs of stabilization, not as proof of a durable turnaround.

07/07/26 03:01 AM ETAI Generated. May Contain Errors.

Oncobiologics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Oncobiologics' financial year ends in September. Their financial year 2024 ended on September 30, 2024.

Oncobiologics' net income appears to be on an upward trend, with a most recent value of -$75.37 million in 2024, rising from -$48.67 million in 2015. The previous period was -$58.98 million in 2023. See Oncobiologics' forecast for analyst expectations on what's next for the company.

Oncobiologics' total operating income in 2024 was -$71.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $71.70 million

Over the last 9 years, Oncobiologics' total revenue changed from $5.22 million in 2015 to $0.00 in 2024, a change of -100.0%.

Oncobiologics' total liabilities were at $50.77 million at the end of 2025, a 50.2% decrease from 2024, and a 18.8% decrease since 2015.

In the past 10 years, Oncobiologics' cash and equivalents has ranged from $1.72 million in 2018 to $23.39 million in 2023, and is currently $8.08 million as of their latest financial filing in 2025.

Over the last 9 years, Oncobiologics' book value per share changed from -5.56 in 2015 to -3.09 in 2024, a change of -44.4%.


Related Companies

Financial statements for NASDAQ:OTLK last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel